Open Label, Multicenter, Phase Ib Trial of CT041, Claudin 18.2 Specific CAR T Cell Therapy As a Consolidation Therapy After Adjuvant Therapy for Resected Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Latest Information Update: 07 Mar 2025
At a glance
- Drugs Cancer vaccine (Primary) ; Satricabtagene autoleucel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Acronyms CT041-CG4010
- Sponsors CARsgen
Most Recent Events
- 07 Mar 2025 Status changed from planning to not yet recruiting.
- 14 Dec 2023 New trial record
- 21 Aug 2023 According to a CARsgen Media Release, the company Collaborates with Moderna to Evaluate CT041 in Combination with an mRNA Cancer Vaccine.